Key points from article :
Researchers, biotechnology companies and investors gathered at Trinity College Dublin for the 2025 Longevity Summit to showcase some of the most promising advances in healthy ageing research. Founded by Aubrey de Grey and Martin O'Dea, the event highlighted the growing shift from studying why we age to developing therapies that could one day prevent or reverse age-related diseases.
Several biotechnology companies presented progress towards clinical applications. NaNotics unveiled its nanotechnology-based approach to removing harmful inflammatory molecules from the bloodstream, with plans to begin clinical trials for multiple sclerosis and future applications in cancer and age-related inflammation. Life Biosciences reported that its partial cellular reprogramming therapy is approaching Phase 1 clinical trials for optic nerve diseases, while Cyclarity Therapeutics announced encouraging early safety results from its first human trial of a treatment designed to remove arterial plaques and potentially tackle heart disease.
Other developments included Global Apheresis, which presented human trial data suggesting therapeutic plasma exchange may reverse some biological markers of ageing, and Accelerated Biosciences, which introduced a new type of ethically sourced stem cell that could be used to develop regenerative therapies for inflammatory and age-related conditions. Researchers from the Buck Institute also highlighted the urgent need for more research into female ageing, arguing that better understanding ovarian ageing could improve women's healthspan.
A common theme throughout the summit was that increasing lifespan and improving healthspan should go hand in hand. While many of the therapies remain experimental, the meeting demonstrated how advances in regenerative medicine, artificial intelligence and biotechnology are steadily moving from the laboratory towards clinical trials, bringing the prospect of treatments that target ageing itself closer to reality.
